Maynard Um
-
-
-
-
-
-
-
Mizuho on Cartesian Therapeutics (RNAC): 'Phase 3 Progress Highlights Underappreciated Descartes-08'
-
-
-
-
-
-
-
Cartesian Therapeutics appoints June Seymour as chief accounting officer
-
-
-
-
-
-
-
Cartesian Therapeutics' (RNAC) Descartes-08 Observed to Provide Deep and Sustained Benefits Through Month 12 After a Single Course of Therapy in Phase 2b Myasthenia Gravis Trial
-
-
-
-
-
-
-
Cartesian Therapeutics (RNAC) PT Raised to $45 at H.C. Wainwright
-
-
-
-
-
-
-
Cartesian Therapeutics (RNAC) Receives FDA Rare Pediatric Disease Designation for Descartes-08 for the Treatment of Juvenile Dermatomyositis
-
-
-
-
-
-
-
Mizuho Reiterates Outperform Rating on Cartesian Therapeutics (RNAC)
-
-
-
-
-
434,406 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

